HRMY
Price
$34.29
Change
+$0.75 (+2.24%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.93B
110 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$22.64
Change
-$0.79 (-3.37%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.82B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HRMY vs SYRE

Header iconHRMY vs SYRE Comparison
Open Charts HRMY vs SYREBanner chart's image
Harmony Biosciences Holdings
Price$34.29
Change+$0.75 (+2.24%)
Volume$4.99K
Capitalization1.93B
Spyre Therapeutics
Price$22.64
Change-$0.79 (-3.37%)
Volume$15.57K
Capitalization1.82B
HRMY vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
HRMY vs. SYRE commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HRMY is a Buy and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (HRMY: $33.54 vs. SYRE: $23.43)
Brand notoriety: HRMY and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HRMY: 96% vs. SYRE: 64%
Market capitalization -- HRMY: $1.93B vs. SYRE: $1.82B
HRMY [@Biotechnology] is valued at $1.93B. SYRE’s [@Biotechnology] market capitalization is $1.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HRMY’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • HRMY’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, HRMY is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HRMY’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • HRMY’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both HRMY and SYRE are a good buy in the short-term.

Price Growth

HRMY (@Biotechnology) experienced а +6.99% price change this week, while SYRE (@Biotechnology) price change was +2.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

HRMY is expected to report earnings on Mar 03, 2026.

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HRMY($1.93B) has a higher market cap than SYRE($1.82B). HRMY has higher P/E ratio than SYRE: HRMY (10.58) vs SYRE (1.72). SYRE YTD gains are higher at: 0.644 vs. HRMY (-2.528). HRMY has higher annual earnings (EBITDA): 265M vs. SYRE (-222.15M). HRMY has more cash in the bank: 565M vs. SYRE (527M). SYRE has less debt than HRMY: SYRE (0) vs HRMY (172M). HRMY has higher revenues than SYRE: HRMY (773M) vs SYRE (0).
HRMYSYREHRMY / SYRE
Capitalization1.93B1.82B106%
EBITDA265M-222.15M-119%
Gain YTD-2.5280.644-392%
P/E Ratio10.581.72617%
Revenue773M0-
Total Cash565M527M107%
Total Debt172M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
86
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
40
P/E GROWTH RATING
1..100
77
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
HRMYSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 17 days ago
77%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
HRMY
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PJRCX9.520.08
+0.85%
PGIM Quant Solutions International Eq C
QMGRX13.570.08
+0.59%
Invesco Advantage International R
PFPRX65.400.16
+0.25%
Parnassus Mid Cap Growth Institutional
POGAX80.660.09
+0.11%
Putnam Large Cap Growth A
FFNIX14.32N/A
N/A
Fidelity Advisor Asset Manager 40% I

HRMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with SNBIF. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then SNBIF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRMY
1D Price
Change %
HRMY100%
+1.70%
SNBIF - HRMY
52%
Loosely correlated
N/A
CYTK - HRMY
37%
Loosely correlated
-0.84%
BMRN - HRMY
35%
Loosely correlated
+0.71%
SYRE - HRMY
32%
Poorly correlated
+0.34%
DAWN - HRMY
31%
Poorly correlated
-0.19%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with APGE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.34%
APGE - SYRE
59%
Loosely correlated
+0.24%
CGON - SYRE
58%
Loosely correlated
+1.47%
IDYA - SYRE
57%
Loosely correlated
-0.19%
RGNX - SYRE
56%
Loosely correlated
+0.43%
NRIX - SYRE
56%
Loosely correlated
-5.37%
More